OMDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Omada Health Inc (OMDA) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. While the company has shown strong revenue growth, its declining net income and EPS, coupled with bearish technical indicators, suggest caution. The lack of significant positive trading signals or news catalysts further supports a hold recommendation.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral at 70.792, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near resistance levels (R1: 12.663, R2: 13.189), which could limit immediate upside potential.
Revenue increased by 49.47% YoY in Q3 2025, and gross margin improved to 66.25%, up 5.58% YoY. Analysts maintain a generally positive outlook with Buy ratings and price targets significantly above the current price.
The stock's bearish moving averages and lack of significant trading trends from hedge funds or insiders indicate limited short-term upside. Additionally, no recent news or congress trading data is available to act as a catalyst.
In Q3 2025, the company showed strong revenue growth of 49.47% YoY, reaching $68.03M. However, net income declined to -$3.18M (-65.55% YoY), and EPS fell to -0.06 (-64.71% YoY). Gross margin improved to 66.25%, up 5.58% YoY.
Analysts have lowered price targets recently (e.g., Goldman Sachs reduced from $29 to $26), but they maintain Buy ratings. Wells Fargo initiated coverage with an Equal Weight rating and a $17 price target, citing partnership tailwinds but highlighting risks related to client concentration and ownership structure. Barclays lowered its price target from $29 to $22 but kept an Overweight rating.
